Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

AstraZeneca829 enrolled

Overview

Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen

Study Type

OBSERVATIONAL

Enrollment

829

Conditions

Prostate Cancer Osteoporosis

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * pathologic confirmation of prostate cancer * patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting. Exclusion Criteria: * patients who are hard to be analysed by limitation of chart record according to investigators'discretion * patients who already have been registered in this study

Locations (18)

Research Site

Cheonan-si, Chungcheongnam-do, South Korea

Research Site

Gangneung-si, Gangwon-do, South Korea

Research Site

Goyang-si, Gyeonggi-do, South Korea

Outcomes

Primary Outcomes

To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.

Secondary Outcomes

To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.